Aptima Combo 2® assay (for CT/NG)

Protect fertility with accurate CT/NG testing.

STIs are on the rise. Chlamydia (CT) and gonorrhea (NG) can have serious long-term consequences including pelvic inflammatory disease (PID), ectopic pregnancy and infertility.1 Accurate testing and treatment are critical to protecting sexual and reproductive health. The Aptima Combo 2® assay delivers reliable results from multiple specimen types, including self and clinician-collected vaginal swabs with the Aptima® Multitest Swab — the preferred specimen type of the CDC for CT and NG testing.

Universal Screening

CDC continues to recommend CT/NG screening for all sexually active women 15-24 years old but recognizes that young women may be hesitant to disclose sexual activity. Thus, CDC recommends that providers might consider an opt-out, or universal, screening approach for adolescent and young adult females.

Universal Screening benefits the lab, healthcare systems, HCPs and patients:
  • Labs are reinforced as trusted partners to HCPs for STI testing and information.
  • Healthcare systems will improve clinical outcomes and quality metrics.
  • HCPs will have fewer uncomfortable conversations, identify and treat more infections, and improve quality metrics.
  • Patients’ reproductive health/ fertility is preserved.